Overview
What is Canine Comparative Oncology And Genomics Consortium Inc?
The Canine Comparative Oncology and Genomics Consortium Inc is a nonprofit organization devoted to addressing the issue of cancer in dogs through collaborative efforts and partnerships. By offering a unique collection of well-documented canine tissues, they provide investigators with valuable resources for developing innovative cancer treatments and prevention strategies. Their mission lies in fostering a multidisciplinary approach, enabling researchers to make significant strides in the field.
Is Canine Comparative Oncology And Genomics Consortium Inc legitimate?
Canine Comparative Oncology And Genomics Consortium Inc is a legitimate nonprofit organization registered as a 501(c)(3) entity. Canine Comparative Oncology And Genomics Consortium Inc submitted a form 990EZ, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
What is the mission statement of Canine Comparative Oncology And Genomics Consortium Inc?
The Canine Comparative Oncology and Genomics Consortium functions as a hub for collaboration and research in the field of canine cancer. By fostering strategic partnerships across various disciplines, the organization aims to tackle the complex problem of cancer in dogs. Through an exclusive repository of well-described canine tissues, the consortium presents valuable opportunities for researchers seeking to develop innovative new treatments and prevention strategies. The consortium's mission is to drive progress in the fight against canine cancer and ultimately improve the lives of affected dogs. The organization's efforts focus on fostering collaboration, providing access to valuable resources, and advancing knowledge in the field.
Who is the CEO of Canine Comparative Oncology And Genomics Consortium Inc?
Dr Michael Kent is the President of Canine Comparative Oncology And Genomics Consortium Inc.
What is the revenue of Canine Comparative Oncology And Genomics Consortium Inc?
Canine Comparative Oncology And Genomics Consortium Inc's revenue in 2022 was $6.
Who are the executives of Canine Comparative Oncology And Genomics Consortium Inc and what are their salaries?
Here are 6 key members and their salaries:
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
Where can I find the form 990EZ for Canine Comparative Oncology And Genomics Consortium Inc?
Canine Comparative Oncology And Genomics Consortium Inc's most recent form 990EZ was submitted in 2022 and can be accessed here.
Mission Statement of Canine Comparative Oncology And Genomics Consortium Inc
Canine Comparative Oncology and Genomics Consortium Inc, a renowned organization, focuses on fostering collaborations and strategic partnerships to tackle the complex issue of cancer in dogs. By providing an extensive repository of well-described canine tissues, this Consortium offers unique opportunities for researchers and institutions, inspiring the development of innovative treatments and prevention strategies.
In pursuit of advancing cancer research, Canine Comparative Oncology and Genomics Consortium Inc builds bridges across diverse scientific disciplines. This collaborative approach ensures that individual investigators gain access to valuable resources and knowledge, ultimately leading to significant strides in canine cancer research. The Consortium's mission is to make a tangible impact on the lives of dogs, while simultaneously contributing to human health and understanding.
The Consortium's exclusive repository of canine tissues presents a novel platform for researchers, enabling them to explore the intricacies of cancer development and progression in dogs. By studying the genetic and molecular underpinnings of canine cancer, researchers can identify commonalities with human cancer, leading to the development of more effective treatments and prevention strategies for both species. Additionally, examining canine cancer provides a unique opportunity to study the disease in real time and observe the effects of treatment interventions, further advancing scientific knowledge.
Through its commitment to collaboration and knowledge-sharing, Canine Comparative Oncology and Genomics Consortium Inc serves as a catalyst for progress in the field of comparative oncology and genomics. Its efforts not only contribute to the well-being of canines but also have the potential to bring about significant advancements in human health.
Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!
Impact
October, 2024
Canine Comparative Oncology and Genomics Consortium Inc plays a crucial role in advancing our understanding and treatment of cancer in dogs. By fostering strategic partnerships across various disciplines, the organization creates a collaborative environment where researchers can unite their expertise to tackle complex cancer issues. This consortium provides access to a unique repository of well-characterized canine tissues, which is invaluable for researchers seeking to develop innovative treatment and prevention strategies.
The initiative not only focuses on canine health but also offers insights that can translate to human medicine, given the biological similarities between dogs and humans. As a result, the consortium significantly advances cancer research by facilitating novel opportunities for both individual and institutional investigators. This impactful work ultimately aims to improve outcomes for dogs suffering from cancer while also contributing to broader advancements in medical science.
This information is meant to be a general summary of Canine Comparative Oncology And Genomics Consortium Inc. Please take the time to review official sources before making any decisions based upon the content provided here.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Investment Income: $6
- Gross Receipts: $6
Assets and Liabilities:
- Total Assets: $83,512
- Total Liabilities: $0
- Net Assets: $83,512
Want to help this charity, for free? You can click here to learn more about Give Freely
Organization Details
Phone
(919) 434-4399Principal Officer
Dr Michael Kent
Main Address
313 MOUNT EDEN PLACE, CARY, NC, 27518
NTEE Category
Code: D05 - Animals
If you are a representative of Canine Comparative Oncology And Genomics Consortium Inc and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.